{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:11:40Z","timestamp":1792289500920,"version":"4.4.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cjca.2021.01.017","type":"journal-article","created":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T20:03:25Z","timestamp":1617566605000},"page":"531-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["CCS\/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1016","volume":"37","author":[{"given":"Michael","family":"McDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anique","family":"Ducharme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri L.","family":"Koshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Mielniczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon W.","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Swiggum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"D\u2019Astous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabe","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.M.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Grzeslo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Heshka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Masoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McKelvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslaw","family":"Rajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Siatecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Storm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Sussex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriette","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia Ming Ching","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2021.01.017_bib1","first-page":"1342","article-title":"2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib2","first-page":"159","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O\u2019Meara","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2021.01.017_bib4","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2021.01.017_bib7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jchf.2020.05.012","article-title":"NT-proBNP response to sacubitril\/valsartan in hospitalized heart failure patients with reduced ejection fraction: TRANSITION study","volume":"8","author":"Pascual-Figal","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2021.01.017_bib8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamacardio.2019.4665","article-title":"Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: secondary analysis of the open-label extension of the PIONEER-HF trial","volume":"5","author":"DeVore","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib10","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jchf.2020.06.008","article-title":"Efficacy and safety of sacubitril\/valsartan by dose level achieved in the PIONEER-HF trial","volume":"8","author":"Berg","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2021.01.017_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cjco.2020.05.009","article-title":"Cost-effectivness of earlier transition to angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction","volume":"2","author":"Grant","year":"2020","journal-title":"CJC Open"},{"key":"10.1016\/j.cjca.2021.01.017_bib12","first-page":"168","article-title":"The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure","volume":"29","author":"McKelvie","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib13","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2021.01.017_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jacc.2008.10.041","article-title":"Acute heart failure syndromes","volume":"53","author":"Gheorghiade","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1161\/CIRCHEARTFAILURE.115.002271","article-title":"Contemporary drug development in heart failure: call for hemodynamically neutral therapies","volume":"8","author":"Vaduganathan","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2021.01.017_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000457946","article-title":"Discontinuation\/dose reduction of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers during acute decompensated heart failure in African-American patients with reduced left-ventricular ejection fraction","volume":"137","author":"Kane","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.cjca.2021.01.017_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.amjmed.2016.05.008","article-title":"Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure","volume":"129","author":"Sanam","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib19","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib20","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) study investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.01.017_bib21","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A\u00a0clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib22","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.01.017_bib23","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.01.017_bib24","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib25","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib26","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.01.017_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.01.017_bib28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7326\/0003-4819-134-7-200104030-00008","article-title":"Beta-blockers in congestive heart failure. A Bayesian meta-analysis","volume":"134","author":"Brophy","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/CCM.0b013e31820a91ed","article-title":"Beneficial association of beta-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial","volume":"39","author":"Bohm","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib31","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/eurheartj\/ehp323","article-title":"B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode","volume":"30","author":"Jondeau","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.01.017_bib32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jacc.2008.03.048","article-title":"Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program","volume":"52","author":"Fonarow","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib33","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jacc.2006.03.030","article-title":"Beta-blocker use and outcomes among hospitalized heart failure patients","volume":"47","author":"Butler","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0002-9149(02)03104-1","article-title":"Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure","volume":"91","author":"Gattis","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jchf.2015.03.008","article-title":"Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis","volume":"3","author":"Prins","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2021.01.017_bib36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib38","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib40","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"413","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.01.017_bib42","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.01.017_bib44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inibitors in patients with heart failure and reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.01.017_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and saftey of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.01.017_bib46","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.01.017_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results fro the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.01.017_bib48","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the dapagliflozin and prevention of adverse outcomes in heart failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.01.017_bib49","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure and reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.01.017_bib50","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib52","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehi190","article-title":"Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease","volume":"26","author":"Diaz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.01.017_bib53","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.01.017_bib54","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ejhf.1682","article-title":"Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction","volume":"22","author":"Docherty","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2021.01.017_bib55","article-title":"Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization","volume":"4","author":"Laskey","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2021.01.017_bib56","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib57","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/eurheartj\/ehn539","article-title":"Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II","volume":"30","author":"Komajda","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.01.017_bib58","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.amjcard.2007.11.023","article-title":"Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers","volume":"101","author":"Flannery","year":"2008","journal-title":"Am J Cardiol"},{"issue":"suppl 2","key":"10.1016\/j.cjca.2021.01.017_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-200767002-00003","article-title":"The funny current: cellular basis for the control of heart rate","volume":"67","author":"DiFrancesco","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.cjca.2021.01.017_bib60","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.01.017_bib61","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ehf2.12513","article-title":"Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b","volume":"6","author":"Bouabdallaoui","year":"2019","journal-title":"m. ESC Heart Fail"},{"key":"10.1016\/j.cjca.2021.01.017_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study","volume":"102","author":"Bohm","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib63","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"MOCHA Investigators. Circulation"},{"key":"10.1016\/j.cjca.2021.01.017_bib64","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1093\/eurheartj\/ehi386","article-title":"Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial","volume":"26","author":"Metra","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.01.017_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004112","article-title":"Ivabradine in heart failure: the representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a broad population of patients with chronic heart failure","volume":"10","author":"Das","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2021.01.017_bib66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2016.04.136","article-title":"Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study","volume":"217","author":"Hidalgo","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib67","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12325-015-0185-5","article-title":"Addition of ivabradine to beta-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study","volume":"32","author":"Bagriy","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.cjca.2021.01.017_bib68","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40261-016-0424-9","article-title":"Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study","volume":"36","author":"Barilla","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cjca.2021.01.017_bib69","doi-asserted-by":"crossref","first-page":"786","DOI":"10.5603\/KP.a2017.0094","article-title":"Effects of ivabradine and beta-blocker therapy on dobutamine-induced ventricular arrhythmias","volume":"75","author":"Mert","year":"2017","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.cjca.2021.01.017_bib70","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.01.017_bib71","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib73","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal pro\u2212B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2021.01.017_bib74","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib75","first-page":"CD002901","article-title":"Digitalis for treatment of heart failure in patients in sinus rhythm","volume":"4","author":"Hood","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2021.01.017_bib76","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2019.05.064","article-title":"Digoxin discontinuation and outcomes in patients with heart failure with reduced ejection fraction","volume":"74","author":"Malik","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.01.017_bib77","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib78","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A\u00a0comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib79","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib80","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.01.017_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.01.017_bib82","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2021.01.017_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"284","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.01.017_bib84","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(11)61219-1","article-title":"Dose-dependent augmentation of cardiac systolic function with selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study","volume":"378","author":"Teerlink","year":"2011","journal-title":"Lancet"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X21000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X21000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:45:55Z","timestamp":1760107555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X21000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0828282X21000556"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2021.01.017","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CCS\/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2021.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}